



## **Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3**

October 25, 2021 at 7:00 AM EDT

LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2021 financial results and operational highlights before open of U.S. markets on Wednesday, November 3, 2021.

Management will host a conference call and webcast at 8:30 am ET/1:30 pm GMT to discuss the company's financial results and provide a general business update. To listen to the webcast and view the accompanying slide presentation, please go to the [events section](#) of Autolus' website.

The call may also be accessed by dialing (866) 679-5407 for U.S. and Canada callers or (409) 217-8320 for international callers. Please reference conference ID 6984737. After the conference call, a replay will be available for one week. To access the replay, please dial (855) 859-2056 for U.S. and Canada callers or (404) 537-3406 for international callers. Please reference conference ID 6984737.

### **Contact:**

Lucinda Crabtree, PhD  
Vice President, Business Strategy and Planning  
+44 (0) 7587 372 619  
[lcrabtree@autolus.com](mailto:lcrabtree@autolus.com)

Julia Wilson  
+44 (0) 7818 430877  
[jwilson@autolus.com](mailto:jwilson@autolus.com)

Susan A. Noonan  
S.A. Noonan Communications  
+1-212-966-3650  
[susan@sanoonan.com](mailto:susan@sanoonan.com)